IL293764A - Compounds for the treatment of familial dysautonomia - Google Patents

Compounds for the treatment of familial dysautonomia

Info

Publication number
IL293764A
IL293764A IL293764A IL29376422A IL293764A IL 293764 A IL293764 A IL 293764A IL 293764 A IL293764 A IL 293764A IL 29376422 A IL29376422 A IL 29376422A IL 293764 A IL293764 A IL 293764A
Authority
IL
Israel
Prior art keywords
methyl
pyrimidin
chloro
amine
thieno
Prior art date
Application number
IL293764A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of IL293764A publication Critical patent/IL293764A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
IL293764A 2019-12-12 2020-12-07 Compounds for the treatment of familial dysautonomia IL293764A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962947049P 2019-12-12 2019-12-12
PCT/US2020/063612 WO2021118929A1 (en) 2019-12-12 2020-12-07 Compounds for treating familial dysautonomia

Publications (1)

Publication Number Publication Date
IL293764A true IL293764A (en) 2022-08-01

Family

ID=74046197

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293764A IL293764A (en) 2019-12-12 2020-12-07 Compounds for the treatment of familial dysautonomia

Country Status (14)

Country Link
US (1) US20230057568A1 (https=)
EP (1) EP4072677A1 (https=)
JP (2) JP2023506488A (https=)
KR (1) KR20220113700A (https=)
CN (1) CN115209955A (https=)
AU (1) AU2020402717A1 (https=)
BR (1) BR112022011364A2 (https=)
CA (1) CA3160053A1 (https=)
CL (1) CL2022001523A1 (https=)
CO (1) CO2022008195A2 (https=)
IL (1) IL293764A (https=)
MX (1) MX2022007094A (https=)
PE (1) PE20221581A1 (https=)
WO (1) WO2021118929A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
MX2024002887A (es) * 2021-09-07 2024-05-28 Ptc Therapeutics Inc Metodos para tratar enfermedades neurodegenerativas.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028964A1 (en) * 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO2005007083A2 (en) * 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
JP2009007341A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
EP2611812A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
CN103242341B (zh) * 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用
CA2973949C (en) * 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
WO2018151326A1 (ja) * 2017-02-20 2018-08-23 国立大学法人京都大学 スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
SG11202108519TA (en) * 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) * 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Also Published As

Publication number Publication date
AU2020402717A1 (en) 2022-06-23
BR112022011364A2 (pt) 2022-08-23
WO2021118929A1 (en) 2021-06-17
KR20220113700A (ko) 2022-08-16
JP2025133750A (ja) 2025-09-11
CO2022008195A2 (es) 2022-07-29
CL2022001523A1 (es) 2023-03-31
US20230057568A1 (en) 2023-02-23
JP2023506488A (ja) 2023-02-16
CA3160053A1 (en) 2021-06-17
PE20221581A1 (es) 2022-10-06
MX2022007094A (es) 2022-07-11
CN115209955A (zh) 2022-10-18
EP4072677A1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
KR102907028B1 (ko) 가족성 자율신경실조증 치료를 위한 티오에노[3,2-b]피리딘-7-아민 화합물
KR20250035623A (ko) 척추소뇌성 운동실조증 유형 3을 치료하기 위한 화합물
US12398140B2 (en) Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
WO2019183589A1 (en) Modulators of eukaryotic initiation factor 2
WO2013066729A1 (en) Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
JP2025133750A (ja) 家族性自律神経失調症を処置するための化合物
AU2021272972A1 (en) HTT modulators for treating Huntington's disease
WO2023039370A1 (en) Methods for treating neurogenerative diseases
AU2020361735B2 (en) 2-azaspiro(3.4)octane derivatives as M4 agonists
CA3181583A1 (en) Methods of use for pyrimidines as ferroportin inhibitors
WO2023091456A1 (en) N-(2h-indazol-5-yl)pyrazine-2-carboxamide derivatives and similar compounds as htt modulators for the treatment of huntington's disease
BR122024013729A2 (pt) Compostos de tieno[3,2-b]piridin-7-amina, seus usos no tratamento de disautonomia familiar e composição farmacêutica compreendendo os mesmos